CN105722524B - 用于重组人分泌球蛋白的改进方法 - Google Patents

用于重组人分泌球蛋白的改进方法 Download PDF

Info

Publication number
CN105722524B
CN105722524B CN201480015596.0A CN201480015596A CN105722524B CN 105722524 B CN105722524 B CN 105722524B CN 201480015596 A CN201480015596 A CN 201480015596A CN 105722524 B CN105722524 B CN 105722524B
Authority
CN
China
Prior art keywords
respiratory
rhscgb3a2
scgb3a2
further object
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480015596.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN105722524A (zh
Inventor
爱普瑞·L·皮隆
梅莉莎·E·温
约翰·K·泽梅尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clarassance Inc
Original Assignee
Clarassance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clarassance Inc filed Critical Clarassance Inc
Publication of CN105722524A publication Critical patent/CN105722524A/zh
Application granted granted Critical
Publication of CN105722524B publication Critical patent/CN105722524B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
CN201480015596.0A 2013-03-15 2014-03-16 用于重组人分泌球蛋白的改进方法 Expired - Fee Related CN105722524B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/843,289 2013-03-15
US13/843,289 US20140274915A1 (en) 2013-03-15 2013-03-15 Methods of Use for Recombinant Human Secretoglobins
PCT/US2014/030101 WO2014145357A2 (en) 2013-03-15 2014-03-16 Improved methods of use for recombinant human secretoglobins

Publications (2)

Publication Number Publication Date
CN105722524A CN105722524A (zh) 2016-06-29
CN105722524B true CN105722524B (zh) 2020-02-21

Family

ID=51529893

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480015596.0A Expired - Fee Related CN105722524B (zh) 2013-03-15 2014-03-16 用于重组人分泌球蛋白的改进方法

Country Status (15)

Country Link
US (5) US20140274915A1 (enExample)
EP (1) EP2968464B1 (enExample)
JP (1) JP6513632B2 (enExample)
KR (1) KR20160011621A (enExample)
CN (1) CN105722524B (enExample)
AU (1) AU2014233116A1 (enExample)
BR (1) BR112015021265A2 (enExample)
CA (1) CA2907395A1 (enExample)
ES (1) ES2883933T3 (enExample)
IL (1) IL241418A0 (enExample)
MX (1) MX2015013091A (enExample)
RU (1) RU2662665C2 (enExample)
SG (1) SG11201507276UA (enExample)
UA (1) UA118756C2 (enExample)
WO (1) WO2014145357A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140274915A1 (en) * 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins
WO2016205430A1 (en) * 2015-06-15 2016-12-22 Therabron Therapeutics, Inc. Recombinant human cc10 protein facilitates repair and protects against damage to the respiratory epithelium due to exposure to both cigarette and other smoke
WO2018178051A1 (en) * 2017-03-28 2018-10-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Scgb1a1 polymorphism for the prediction and therapy or prevention of primary graft dysfunction
WO2019143934A1 (en) 2018-01-19 2019-07-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cancer activity of scbg3a2 and lps
AU2019387570A1 (en) * 2018-11-30 2021-07-15 Apc Research Assets Llc Compositions and methods of use for secretoglobins to protect the glycocalyx via interactions with heparan sulfate proteoglycan proteins
KR20200138684A (ko) * 2020-11-17 2020-12-10 김유신 토양 파쇄기를 장착한 친환경 고온스팀 토양소독기
WO2023212398A1 (en) * 2022-04-29 2023-11-02 Apc Research Assets Llc Secretoglobins for suppression of antibody responses
CN119631983B (zh) * 2024-12-30 2025-07-22 西南医科大学 一种心脏原发性肿瘤小鼠模型的构建方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040047857A1 (en) 1997-05-28 2004-03-11 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20030008816A1 (en) 1997-05-28 2003-01-09 Pilon Aprile L. Methods and compositions for the treatment of fibrotic conditions & impaired lung function & to enhance lymphocyte production
US20060281681A1 (en) * 1997-05-28 2006-12-14 Pilon Aprile L Methods and compositions for the reduction of neutrophil influx and for the treatment of bronchpulmonary dysplasia, respiratory distress syndrome, chronic lung disease, pulmonary fibrosis, asthma and chronic obstructive pulmonary disease
AU5551299A (en) 1998-08-13 2000-03-06 Trustees Of The University Of Pennsylvania, The Method of identifying proteins
US6953666B1 (en) 1998-11-06 2005-10-11 Emory University Biomarkers for oxidative stress
WO2004101824A1 (ja) * 2003-05-14 2004-11-25 Shionogi & Co., Ltd. 慢性閉塞性肺疾患の検出方法
US7655413B2 (en) * 2003-06-26 2010-02-02 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
KR20060111508A (ko) 2003-11-14 2006-10-27 알자 코포레이션 조사된 부형제 약물 제형에서 약물 산화 최소화
US20060275794A1 (en) * 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
JP2007059191A (ja) 2005-08-24 2007-03-08 Kazuo Kono 照明器具駆動回路
WO2008039941A2 (en) * 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
US20090004684A1 (en) 2007-05-23 2009-01-01 Claudia Susanne Maier Compositions and Methods for Detection and Quantification of Protein Oxidation
DK2488205T3 (en) 2009-10-15 2017-01-16 Therabron Therapeutics Inc Recombinant human CC10 protein for the treatment of influenza
RU2439569C1 (ru) * 2010-11-12 2012-01-10 Федеральное государственное учреждение "Ивановский научно-исследовательский институт материнства и детства имени В.Н. Городкова" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования бронхолегочной дисплазии у детей с врожденной пневмонией
US20140274915A1 (en) 2013-03-15 2014-09-18 Clarassance, Inc. Methods of Use for Recombinant Human Secretoglobins

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
An update on pharmacologic approaches to bronchopulmonary dysplasia;Sailaja等;《SciVerse ScienceDirect》;20130401;第37卷;第115-123页 *
CC10 蛋白功能及在疾病中的作用研究进展;魏颖等;《中国医药生物技术》;20111031;第6卷(第5期);第359-363页 *
Intratracheal Clara cell secretory protein (CCSP) administration in preterm infants with or at risk of respiratory distress syndrome (Protocol);Mohamed等;《John Wiley & Sons, Ltd》;20110511(第1期);第1-9页 *
Preclinical evaluation of human secretoglobin 3A2 in mouse models of lung development and fibrosis;Cai等;《AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY》;20140131;第306卷(第1期);第L10-L22页 *
Safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome;Levine等;《PEDIATRIC RESEARCH》;20050731;第58卷(第1期);第15-21页 *

Also Published As

Publication number Publication date
AU2014233116A1 (en) 2015-09-24
US9765127B2 (en) 2017-09-19
UA118756C2 (uk) 2019-03-11
US20180244735A1 (en) 2018-08-30
MX2015013091A (es) 2016-10-07
US20200262878A1 (en) 2020-08-20
US20240376162A1 (en) 2024-11-14
US11512121B2 (en) 2022-11-29
EP2968464A2 (en) 2016-01-20
CA2907395A1 (en) 2014-09-18
KR20160011621A (ko) 2016-02-01
RU2662665C2 (ru) 2018-07-26
CN105722524A (zh) 2016-06-29
JP6513632B2 (ja) 2019-05-15
US10556938B2 (en) 2020-02-11
EP2968464A4 (en) 2016-11-09
ES2883933T3 (es) 2021-12-09
RU2015144359A (ru) 2017-04-25
US20160159870A1 (en) 2016-06-09
IL241418A0 (en) 2015-11-30
BR112015021265A2 (pt) 2017-10-10
WO2014145357A2 (en) 2014-09-18
EP2968464B1 (en) 2021-05-05
US20140274915A1 (en) 2014-09-18
JP2016520531A (ja) 2016-07-14
SG11201507276UA (en) 2015-10-29
WO2014145357A3 (en) 2014-12-31

Similar Documents

Publication Publication Date Title
CN105722524B (zh) 用于重组人分泌球蛋白的改进方法
US9611307B2 (en) Method for increasing granulocyte number in a patient by administering superactive IL-33 fragments
WO2007109118A9 (en) RECOMBINANT HUMAN CC 10 (rhCC10) FOR TREATMENT OF RESPIRATORY DISORDERS
EP3459556A1 (en) Synthetic analogs of lung surfactant protein sp-c and their use
CA3087835A1 (en) Modified protein
WO2021198395A1 (en) Surfactant protein d for use in treating coronavirus infections
CN110831957B (zh) Apoc-ii模拟肽
CN106046171A (zh) 用于防治阿尔茨海默病的融合蛋白及其制备方法和应用
CN110548135B (zh) 磷酸化多肽抗原疫苗及其制备方法和应用
CN102134279B (zh) 融合蛋白及其编码基因与应用
CN114853911B (zh) 三叶因子2/干扰素α2融合蛋白及其防治病毒感染性疾病的应用
EP4530300A1 (en) Trefoil factor 2/interferon alpha2 fusion protein and application thereof in prevention and treatment of viral infectious diseases
WO2021241240A1 (ja) 抗緑膿菌ワクチンに有用なタンパク質分子
CN106540242B (zh) IL-1F7a的作用
WO2024235270A1 (zh) 补体抑制剂及其制备方法和用途
HK40084128A (en) Coronavirus antibody and use thereof
WO2025114429A1 (en) Transcytosing composition
WO2023154841A2 (en) Sars-cov-2 neutralizing synthetic proteins
CN121100127A (zh) 新型治疗性多肽
HK40064258B (zh) 新重组二胺氧化酶及其治疗以过量组胺为特徵的疾病的用途
JP2022520862A (ja) 新規組換えジアミンオキシダーゼおよび過剰ヒスタミンによって特徴づけられる疾患の治療のためのその使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200221